Launch of Eversense 365: First Year-Long Implantable CGM by Senseonics
Senseonics has introduced Eversense 365, a year-long implantable continuous glucose monitor (CGM), which is compatible with insulin pumps. This innovation marks a significant advancement in diabetes management technology.
Theia Market Signal Identification - AI Assisted
Senseonics launched the Eversense 365 in 2024, an implantable continuous glucose monitor designed to remain under the skin for one year. The device allows users to change its external adhesive daily with minimal skin irritation.
As an integrated CGM (iCGM), Eversense 365 can interface with compatible medical devices, including insulin pumps, and debuted with the Sequel Med Tech twiist pump. The development of Eversense 365 reflects ongoing advancements in diabetes management technologies, potentially improving patient outcomes and enhancing automated insulin delivery systems.
Comments